"ROLE OF ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA IN THE ERA OF NEW DRUGS"

High-dose melphalan with autologous stem cell rescue has been regarded as the standard of care for patients with newly diagnosed myeloma up to the age of 65-70 years. The recent development of agents with potent anti-tumor activity such as thalidomide, lenalidomide and bortezomib has further improve...

Full description

Bibliographic Details
Published in:	Mediterranean Journal of Hematology and Infectious Diseases
Main Authors:	Benedetto Bruno, Luisa Giaccone, Moreno Festuccia, Mario Boccadoro
Format:	Article
Language:	English
Published:	PAGEPress Publications 2010-06-01
Subjects:	myeloma, transplantation
Online Access:	http://www.mjhid.org/index.php/mjhid/article/view/176

Similar Items

Allogeneic stem cell transplantation in multiple myeloma: is there still a place?
by: Carmine Liberatore, et al.
Published: (2024-06-01)

Allogeneic transplantation in multiple myeloma Transplante alogênico no mieloma múltiplo
by: Ignazio Majolino, et al.
Published: (2009-08-01)

UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
by: Patrizia Tosi, et al.
Published: (2012-01-01)

UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
by: Patrizia Tosi, et al.
Published: (2012-11-01)

Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy
by: Serena Rocchi, et al.
Published: (2024-05-01)

Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of New Drugs
by: OV Pirogova, et al.
Published: (2018-04-01)

Daratumumab‐based induction and autologous transplantation in concomitant multiple myeloma and chronic myeloid leukemia
by: Carmine Liberatore, et al.
Published: (2023-11-01)

AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: IS IT STILL THE RIGHT CHOICE?
by: Patrizia Tosi
Published: (2014-07-01)

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide
by: Andrew D. Trunk, et al.
Published: (2023-01-01)

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
by: Francesca Bonello, et al.
Published: (2020-12-01)

The impact of multiple myeloma drugs treatments on autologous stem cell transplantation in the era of new drugs
by: Xixi Wan, et al.
Published: (2025-02-01)

Hematopoietic stem cell transplantation in the treatment of multiple myeloma
by: Angelo Maiolino
Published: (2002-01-01)

Survival and response deepening after autologous transplantation in patients with multiple myeloma in Chile
by: María Carolina Guerra, et al.
Published: (2022-12-01)

Multiple Myeloma Complicated With Bronchiolitis Obliterans Syndrome After Allogeneic Haematopoietic Stem Cell Transplantation and Subsequently Underwent Lung Transplantation Successfully: A Case Report
by: Shih‐Wei Huang, et al.
Published: (2025-03-01)

Relapsed Multiple Myeloma Presenting as Intracranial Plasmacytoma and Malignant Pericardial Effusion following Recent Allogeneic Stem Cell Transplantation
by: Jonathan Pan, et al.
Published: (2017-07-01)

Real‐world multiple myeloma front‐line treatment and outcomes by transplant in the United States
by: Joshua Richter, et al.
Published: (2023-11-01)

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
by: Samer A. Srour, et al.
Published: (2021-08-01)

Effective use of intensive treatment against multiple myeloma of recipient origin after allogeneic transplantation for acute myeloid leukemia
by: Félicité de Charry, et al.
Published: (2023-01-01)

Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplant in Multiple Myeloma Patients: A 5-year Experience from a Single Centre in North India
by: Nitin Sood, et al.
Published: (2023-04-01)

Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years
by: Si Yu Lin, et al.
Published: (2024-07-01)

Retrospective Analysis of Patients with Multiple Myeloma Post Autologous Stem Cell Transplant
by: Disha SATYA, et al.
Published: (2025-09-01)

Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era
by: Huixing Zhou, et al.
Published: (2023-04-01)

Real World Predictors, Timing, and Outcomes of Autologous Stem Cell Transplantation in Patients with Multiple Myeloma
by: Lisa Blackburn, et al.
Published: (2024-10-01)

Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy
by: Charlotte F. M. Hughes, et al.
Published: (2024-03-01)

Corrigendum: Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years
by: Si Yu Lin, et al.
Published: (2025-03-01)

Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: a systematic review and meta-analysis
by: Min Wei, et al.
Published: (2023-12-01)

Tandem Versus Single Autologous Stem Cell Transplantation for High‐Risk Multiple Myeloma in the Era of Novel Agents: A Real‐World Study of China
by: Xuelin Dou, et al.
Published: (2025-01-01)

Comparison of single and double autologous stem cell transplantation in multiple myeloma patients
by: Malkan Umit Yavuz, et al.
Published: (2021-01-01)

EFFECTS OF DARATUMUMAB ON HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA WHO ARE PLANNED TO RECEIVE AUTOLOGOUS TRANSPLANTATION: WHAT’S THE RELEVANCE?
by: Pellegrino Musto, et al.
Published: (2024-08-01)

Outcomes of melphalan 140 mg/m2 followed by autologous stem cell transplantation in multiple myeloma patients with co‐morbidities: Single‐centre experience
by: Dario Melotti, et al.
Published: (2024-10-01)

How I manage frontline transplant-eligible multiple myeloma in Italy
by: Vittorio Montefusco, et al.
Published: (2020-09-01)

The use of non-cryopreserved hematopoietic stem cells for autologous transplantation in multiple myeloma patients
by: S. V. Voloshin, et al.
Published: (2022-04-01)

The Role of Radiotherapy for Patients With Multiple Myeloma in the Modern Era: A Real World Single‐Centre Experience
by: Dipal Mehta, et al.
Published: (2025-10-01)

Result of Bortezomib Induction Therapy Prior to Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Cases in Mongolia
by: Khishigjargal Batsukh, et al.
Published: (2017-06-01)

Busulfan and cyclophosphamide for autologous stem cell transplantation in patients with multiple myeloma after proteasome inhibitor and/or immunomodulatory drug treatment
by: Min Ji Jeon, et al.
Published: (2024-11-01)

Insights from Clinical Trials: Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma
by: Olga Lytvynova, et al.
Published: (2024-09-01)

Therapy efficacy in multiple myeloma patients received autologous stem cells transplantation as first line therapy
by: Ye. I. Darskaya, et al.
Published: (2014-07-01)

Therapy efficacy in multiple myeloma patients received autologous stem cells transplantation as first line therapy
by: Ye. I. Darskaya, et al.
Published: (2014-07-01)

FIFTEEN YEARS OF SINGLE CENTER EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: A RETROSPECTIVE ANALYSIS
by: Jakub Radocha, et al.
Published: (2013-01-01)

Autologous Hematopoietic Cell Transplant as an Effective Treatment Modality for Systemic Sclerosis and Multiple Myeloma
by: Memon H, et al.
Published: (2025-01-01)